After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.

#RhythmPharma has secured the first approval in the US for a drug to treat #hypothalamicobesity, a #rarecondition in which damage to or a malfunction of the hypothalamus leads to excessive #weightgain.

Weekly Roundup - PHARMA - 6 January 2025 🔊BMS's Opdivo Qvantig FDA-Approved for Subcutaneous Use in NSCLC and Solid Tumors Bristol Myers Squibb's Opdivo Qvantig receives FDA approval for subcutaneous use in NSCLC and other solid tumors. The ...

Weekly Roundup - PHARMA - 6 January 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#FDA #Hikma #GLP1 #Victoza #EliLilly #Zepbound #ObesityTreatment #RhythmPharma #Setmelanotide #Imcivree #GeneticObesity #Pfizer #Braftovi #Humanteconomy #Humantec #KStrategyand

Weekly Roundup - PHARMA - 30 December 2024 🔊FDA Approves Hikma's First Generic GLP-1 Injection for Type 2 Diabetes The FDA has approved the first generic daily GLP-1 injection for type 2 diabetes, referencing Novo Nordisk’s Victoza. The approv...

Weekly Roundup - PHARMA - 30 December 2024

Click here to read more ➡ www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#FDA #Hikma #GLP1 #Victoza #EliLilly #Zepbound #ObesityTreatment #RhythmPharma #Setmelanotide #Imcivree #Humanteconomy #Humantec #KStrategyand